Overall survival | Progression-free survival | |||||
---|---|---|---|---|---|---|
HR | 95% CI | Wald’s p | HR | 95% CI | Wald’s p | |
Group | ||||||
XELIRI-Bev | 1 | 1 | ||||
FOLFIRI-Bev | 0.842 | 0.587–1.207 | 0.35 | 0.949 | 0.682–1.321 | 0.76 |
Performance status | ||||||
0 | 1 | 1 | ||||
1–2 | 1.710 | 1.164–2.513 | 0.006 | 1.375 | 0.952–1.986 | 0.090 |
Number of organs involved | ||||||
1 | 1 | 1 | ||||
2 | 1.580 | 1.052–2.373 | 0.027 | 1.475 | 1.019–2.135 | 0.040 |
≥3 | 2.598 | 1.502–4.493 | 0.001 | 2.305 | 1.337–3.973 | 0.003 |
Osteopontin (OPN) | ||||||
Low | 1 | 1 | ||||
High | 1.632 | 1.116–2.387 | 0.012 | 1.467 | 1.044–2.060 | 0.027 |